Consensus $3.34. Narrows 2025 revenue view to $3.15B-$3.2B from $3.125B-$3.2B, consensus $3.17B. This note corrects the consensus in a prior version.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin lowers 2025 non-GAAP EPS $3.50-$3.60 from $4.40-$4.55, consensus $3.84
- BioMarin’s Vosoritide Study: A Potential Game-Changer for Hypochondroplasia Treatment
- BioMarin’s Vosoritide Study: A Potential Game-Changer in Pediatric Growth Disorders
- BioMarin’s Long-Term Study on BMN 270: A Potential Game Changer for Hemophilia A
- BioMarin’s Vosoritide Study: A Long-Term Hope for Hypochondroplasia